$RGLS
Regulus Therapeutics Inc.

2015 Q1 Form 10-Q Financial Statement

#000119312515177520 Filed on May 08, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q1
Revenue $4.200M $1.631M
YoY Change 157.51% -49.63%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.640M $2.730M
YoY Change 33.33% 42.93%
% of Gross Profit
Research & Development $13.43M $9.604M
YoY Change 39.81% 39.53%
% of Gross Profit
Depreciation & Amortization $394.0K $354.0K
YoY Change 11.3% 22.49%
% of Gross Profit
Operating Expenses $17.07M $12.34M
YoY Change 38.38% 40.37%
Operating Profit -$12.87M -$10.71M
YoY Change 20.23% 92.88%
Interest Expense $8.000K $11.00K
YoY Change -27.27% -84.29%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$14.49M -$12.74M
YoY Change 13.74% 75.99%
Income Tax -$4.000K $1.000K
% Of Pretax Income
Net Earnings -$14.49M -$12.74M
YoY Change 13.7% 76.25%
Net Earnings / Revenue -344.93% -781.18%
Basic Earnings Per Share -$0.29 -$0.30
Diluted Earnings Per Share -$3.475M -$0.30
COMMON SHARES
Basic Shares Outstanding 50.52M shares 43.17M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.8M $114.6M
YoY Change 29.84% 26.35%
Cash & Equivalents $19.60M $8.476M
Short-Term Investments $129.2M $106.1M
Other Short-Term Assets $4.900M $3.500M
YoY Change 40.0% 218.18%
Inventory
Prepaid Expenses
Receivables $4.900M $100.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $158.5M $118.2M
YoY Change 34.08% 28.83%
LONG-TERM ASSETS
Property, Plant & Equipment $3.444M $3.805M
YoY Change -9.49% -2.24%
Goodwill
YoY Change
Intangibles $1.087M $1.095M
YoY Change -0.73% -6.89%
Long-Term Investments
YoY Change
Other Assets $1.800M $978.0K
YoY Change 84.05% 414.74%
Total Long-Term Assets $6.331M $5.878M
YoY Change 7.71% 11.79%
TOTAL ASSETS
Total Short-Term Assets $158.5M $118.2M
Total Long-Term Assets $6.331M $5.878M
Total Assets $164.8M $124.1M
YoY Change 32.83% 27.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.677M $2.691M
YoY Change -0.52% 576.13%
Accrued Expenses $5.318M $3.279M
YoY Change 62.18% 40.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $14.35M $9.568M
YoY Change 49.99% -24.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $13.40M
YoY Change -100.0% 12.61%
Other Long-Term Liabilities $903.0K $1.361M
YoY Change -33.65% 69.28%
Total Long-Term Liabilities $903.0K $1.361M
YoY Change -33.65% 69.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.35M $9.568M
Total Long-Term Liabilities $903.0K $1.361M
Total Liabilities $18.02M $31.82M
YoY Change -43.36% -22.69%
SHAREHOLDERS EQUITY
Retained Earnings -$150.3M -$91.83M
YoY Change 63.63% 35.74%
Common Stock $297.2M $43.00K
YoY Change 691160.47% 19.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $146.8M $92.29M
YoY Change
Total Liabilities & Shareholders Equity $164.8M $124.1M
YoY Change 32.83% 27.91%

Cashflow Statement

Concept 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$14.49M -$12.74M
YoY Change 13.7% 76.25%
Depreciation, Depletion And Amortization $394.0K $354.0K
YoY Change 11.3% 22.49%
Cash From Operating Activities -$11.25M -$9.029M
YoY Change 24.62% 26.19%
INVESTING ACTIVITIES
Capital Expenditures $236.0K $75.00K
YoY Change 214.67% -2.6%
Acquisitions
YoY Change
Other Investing Activities -$7.150M -$10.41M
YoY Change -31.32% -33.57%
Cash From Investing Activities -$7.390M -$10.48M
YoY Change -29.5% -33.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $257.0K $9.728M
YoY Change -97.36% 11344.71%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $915.0K 10.18M
YoY Change -91.01% 5784.97%
NET CHANGE
Cash From Operating Activities -$11.25M -9.029M
Cash From Investing Activities -$7.390M -10.48M
Cash From Financing Activities $915.0K 10.18M
Net Change In Cash -$17.73M -9.331M
YoY Change 89.98% -58.95%
FREE CASH FLOW
Cash From Operating Activities -$11.25M -$9.029M
Capital Expenditures $236.0K $75.00K
Free Cash Flow -$11.49M -$9.104M
YoY Change 26.19% 25.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
51017405 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8476000
CY2015Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.00
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50762489 shares
CY2015Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9799795 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.86
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6606000 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50762489 shares
CY2015Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2769000
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
14351000
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-163000
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1049000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2677000
CY2015Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
903000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
146825000
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
297191000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-150254000
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5307000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5318000
CY2015Q1 us-gaap Liabilities
Liabilities
18023000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
51000
CY2015Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
0
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
164848000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1800000
CY2015Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
4859000
CY2015Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1087000
CY2015Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
148182000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3444000
CY2015Q1 us-gaap Assets
Assets
164848000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19600000
CY2015Q1 us-gaap Short Term Investments
ShortTermInvestments
129191000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4867000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
158517000
CY2015Q1 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
129297000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17807000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48944530 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.95
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6643000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48944530 shares
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3252000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35192000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-197000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2108000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2188000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1022000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
132014000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
267929000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135767000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3097000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4402000
CY2014Q4 us-gaap Liabilities
Liabilities
39466000
CY2014Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
23397000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
49000
CY2014Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
23400000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
171480000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1811000
CY2014Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
274000
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1150000
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
159488000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3568000
CY2014Q4 us-gaap Assets
Assets
171480000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37327000
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
122416000
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4934000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
164951000
CY2014Q4 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
122580000
CY2015Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.00
CY2015Q1 us-gaap Share Price
SharePrice
18.58
CY2015Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1356738 shares
CY2012Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2015-10-09
CY2014 us-gaap Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
1.10 pure
CY2014 us-gaap Fair Value Inputs Entity Credit Risk
FairValueInputsEntityCreditRisk
0.097 pure
CY2014 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0010 pure
CY2014 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
3000
CY2014 us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
167000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9029000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42690200 shares
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3775379 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
75000
CY2014Q1 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-2124000
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-43000
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
CY2014Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
39780000
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12740000
CY2014Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
301000
CY2014Q1 us-gaap Interest Paid
InterestPaid
11000
CY2014Q1 us-gaap Revenues
Revenues
1631000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
385000
CY2014Q1 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
34000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12784000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10705000
CY2014Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
61000
CY2014Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
100000
CY2014Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-18000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-12741000
CY2014Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-442000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10181000
CY2014Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-61000
CY2014Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-438000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2732000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1400000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9331000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10483000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
12336000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1161000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11252000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-39000
CY2014Q1 us-gaap Interest Expense
InterestExpense
11000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1519000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9728000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
487000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
354000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1400000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9604000
CY2014Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
29372000
CY2015Q1 dei Trading Symbol
TradingSymbol
RGLS
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
REGULUS THERAPEUTICS INC.
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001505512
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
413000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.39
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50071165 shares
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
423000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.36
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2813279 shares
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</p> </div>
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.64
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
27000 shares
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-17727000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-7390000
CY2015Q1 us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
114000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
236000
CY2015Q1 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-1811000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
58000
CY2015Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
CY2015Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
37157000
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14491000
CY2015Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
14000
CY2015Q1 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
8000
CY2015Q1 us-gaap Interest Paid
InterestPaid
8000
CY2015Q1 us-gaap Revenues
Revenues
4200000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-78000
CY2015Q1 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
37000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14434000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12871000
CY2015Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
7000
CY2015Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
2469000
CY2015Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
199000
CY2015Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-50000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-14487000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-425000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
915000
CY2015Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-79000
CY2015Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1059000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3644000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3103000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
17071000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-389000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
899000
CY2015Q1 us-gaap Interest Expense
InterestExpense
8000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
471000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
257000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
695000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
394000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3103000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13427000
CY2015Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
30010000

Files In Submission

Name View Source Status
0001193125-15-177520-index-headers.html Edgar Link pending
0001193125-15-177520-index.html Edgar Link pending
0001193125-15-177520.txt Edgar Link pending
0001193125-15-177520-xbrl.zip Edgar Link pending
d899387d10q.htm Edgar Link pending
d899387dex105.htm Edgar Link pending
d899387dex311.htm Edgar Link pending
d899387dex312.htm Edgar Link pending
d899387dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20150331.xml Edgar Link completed
rgls-20150331.xsd Edgar Link pending
rgls-20150331_cal.xml Edgar Link unprocessable
rgls-20150331_def.xml Edgar Link unprocessable
rgls-20150331_lab.xml Edgar Link unprocessable
rgls-20150331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending